Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Iqirvo (elafibranor) receives FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis – Ipsen

Written by | 24 Jun 2024

Ipsen announced that the FDA has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid… read more.

Intercept Pharmaceuticals Inc. announces updates to Ocaliva prescribing information for primary biliary cholangitis

Written by | 29 May 2021

Intercept Pharmaceuticals, Inc. announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has been updated.The changes to the Ocaliva Prescribing Information were prompted… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.